Provided by Tiger Trade Technology Pte. Ltd.

INDIVIOR PLC

35.83
+0.38001.07%
Post-market: 35.830.00000.00%16:38 EDT
Volume:3.78M
Turnover:135.38M
Market Cap:4.23B
PE:12.95
High:36.14
Open:35.45
Low:35.21
Close:35.45
52wk High:42.81
52wk Low:22.95
Shares:118.00M
Float Shares:109.00M
Volume Ratio:1.82
T/O Rate:3.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.77
EPS(LYR):1.64
ROE:12.20%
ROA:26.40%
PB:-20.33
PE(LYR):21.85

Loading ...

Supernus Pharmaceuticals Shares Rise 5.3% Premarket After Co to Merge with Indivior Pharmaceuticals

THOMSON REUTERS
·
Aug 03

Indivior Q2 FY26 GAAP Net Income Rises to $122 Million; Revenue Increases 14% to $343 Million YoY

Reuters
·
Aug 03

Indivior Pharmaceuticals Q2 Revenue USD 343 Million Vs. IBES Estimate USD 307.6 Million

Reuters
·
Aug 03

Indivior Pharmaceuticals Outlook FY Revenue USD 1,295-1,365 Million

THOMSON REUTERS
·
Aug 03

Press Release: Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

Dow Jones
·
Aug 03

Supernus, Indivior Agree All-Stock Merger, Combined Firm to Trade as Supernus on NASDAQ

Reuters
·
Aug 03

Supernus Pharmaceuticals - Stockholders Will GET 1.5401 Common Shares of Indivior Pharmaceuticals for Each Share of Supernus Pharmaceuticals They Own

THOMSON REUTERS
·
Aug 03

Supernus Pharmaceuticals Inc: Indivior Pharmaceuticals Stockholders Will Own Approximately 56.5% of Combined Company

THOMSON REUTERS
·
Aug 03

Supernus: Combined Co Expected to Benefit from Immediate Scale and $125 Mln of Expected Annual Cost Synergies

THOMSON REUTERS
·
Aug 03

Supernus: Indivior Pharmaceuticals Stockholders to GET One-Time Special Cash Dividend of $1 Bln in Aggregate Immediately Prior to Closing of Merger

THOMSON REUTERS
·
Aug 03

Supernus Pharmaceuticals Inc - Definitive Agreement to Combine in a Tax-Free All-Stock Merger

THOMSON REUTERS
·
Aug 03

Supernus Pharmaceuticals Inc - Combined Entity to be Named Supernus, Inc. and Jack Khattar to Serve as President and Chief Executive Officer

THOMSON REUTERS
·
Aug 03

Earning Preview: INDIVIOR PLC Q2 revenue is expected to increase by 25.79%, and institutional views are bullish

Earnings Agent
·
Jul 29

Indivior to Report Q2 2026 Results, Host Webcast Presentation

Reuters
·
Jul 23

Rxsight Names Aziz Mottiwala CEO, Ron Kurtz to Become Chief Medical Officer

Reuters
·
Jul 16

Indivior CSO Christian Heidbreder Disposes of $764,432.04 in Common Shares

Reuters
·
Jul 14

Indivior Pharmaceuticals (INDV) Pushes Cost Cuts And Growth, Is It Still 17% Undervalued?

Simply Wall St.
·
Jun 26

Indivior Pharmaceuticals Initiated at Overweight by Barclays

Dow Jones
·
Jun 18

Indivior Pharmaceuticals, Inc :  Barclays Initiates Coverage With Overweight Rating and Target Price $46

THOMSON REUTERS
·
Jun 18

Barclays Initiates Indivior at Overweight With $46 Price Target

MT Newswires Live
·
Jun 18